来中国看病的外国人远没有到"扎堆"的地步。经济观察报记者 走访了多家头部医院的国际部，几乎没有看到外国人。有学者 指出，国际医疗旅游还在萌芽期。 作者： 刘晓诺 等 封图：受访者供图 1月17日，英国人Sabrina在上海做过视力检查后，来到西安参观了她30年前就想看的兵马俑，终 得一窥2200年前的中国。 得益于签证政策放宽，Sabrina在1月初首次来华旅游，第一站是复旦大学附属耳鼻喉医院。 Sabrina想做近视手术，在英国看过两次门诊都不满意，想听中国医生的建议。 中国医院让她印象最深的是诊疗效率。 "在英国，如果我们没有预约就去医院，可能要等好几个小时甚至好几个月，才能见到医生，这取 决于我们离失明有多接近。每次预约都在不同的日期，我们每次都要回答大约30个问题，大部分 是重复的，还要一遍遍做同样的血液、尿液、血压检查。"她说。 Sabrina到复旦大学附属耳鼻喉医院时，是上午11点，还有余号，医护人员很快帮她挂了号、做检 查，当天17点她就可以离开医院了。医生建议她先不做手术，并把检查资料都给了她，以便她日 后咨询英国医生。 此后，Sabrina继续旅行。除了西安，她还去了丽江和香格里拉，实现了她 ...

Core Viewpoint - International Medical (000516) forecasts a net profit loss of between -295 million to -315 million yuan for 2025, representing a year-on-year decline of 16.08% to 23.95% [1] Group 1: Financial Performance - The company expects a significant decrease in net profit for 2025, indicating ongoing financial challenges [1] - The anticipated loss is attributed to market fluctuations and reforms in the DRG payment policy, which have negatively impacted revenue [1] Group 2: Operational Adjustments - In response to the adverse conditions, the company is adjusting its business structure and implementing cost reduction and efficiency improvement measures [1] - Despite these efforts, the total revenue generated in the fourth quarter has not yet covered operational costs and period expenses [1]

Group 1 - The company, Dian Diagnostics, announced an expected net profit for the year 2025, ranging from 28 million to 42 million yuan, a significant turnaround from a loss of 357.28 million yuan in the previous year [2]

齐鲁晚报.齐鲁壹点孙淑玉吕奇通讯员潘峰潘晶张国杰 1月26日上午，烟台市烟台山医院东院区门诊楼前广场，伴随着一架载有医疗物资的无人机腾空而起，烟台市低空医疗配送首飞成功。据悉，这也是山东 省首个医院院区间医疗物资智能低空运送场景的正式首飞。此举标志着烟台医疗服务从"地面覆盖"向"空地协同"的跨越式升级，为全省"医疗+交通"融合 发展提供了可复制、可推广的"烟台样板"。 首飞仪式由烟台市烟台山医院党委委员、副院长孙涛主持。"医疗急救的核心是与时间赛跑，低空医疗配送的落地，正重塑医疗急救的时间维度与空间边 界。"烟台市烟台山医院党委书记、院长姜俊杰在致辞中介绍，此次启用的低空医疗配送体系，可实现急救物资、血制品、病理样本等医疗用品的高效精 准转运，这一创新实践，既是对山东省低空经济发展战略的精准响应，也是落实烟台市委、市政府建设绿色低碳高质量发展示范城市建设目标的具体举 措，更是紧扣烟台市"十五五"规划部署，瞄准2026年"低空智航"重点任务开展的医疗先行与路径探索。 首飞航线沿烟台山医院东院区至烟台山医疗集团高新区医院的专用航线起飞，无人机在7分钟内平稳完成医疗物资运载，高效完成首飞任务。据悉，本次 投入使用的 ...

经济观察报 记者 刘晓诺 张锐 实习记者 田韫莘 1月17日，英国人Sabrina在上海做过视力检查后，来到西安参观了她30年前就想看的兵马俑，终得一窥 2200年前的中国。 得益于签证政策放宽，Sabrina在1月初首次来华旅游，第一站是复旦大学附属耳鼻喉医院。Sabrina想做 近视手术，在英国看过两次门诊都不满意，想听中国医生的建议。 中国医院让她印象最深的是诊疗效率。 "在英国，如果我们没有预约就去医院，可能要等好几个小时甚至好几个月，才能见到医生，这取决于 我们离失明有多接近。每次预约都在不同的日期，我们每次都要回答大约30个问题，大部分是重复的， 还要一遍遍做同样的血液、尿液、血压检查。"她说。 Sabrina到复旦大学附属耳鼻喉医院时，是上午11点，还有余号，医护人员很快帮她挂了号、做检查， 当天17点她就可以离开医院了。医生建议她先不做手术，并把检查资料都给了她，以便她日后咨询英国 医生。 此后，Sabrina继续旅行。除了西安，她还去了丽江和香格里拉，实现了她多年来在中国自由行的愿 望。 2024年底，中国签证政策全面放宽，目前已对几十个国家的公民实行240小时或30天免签。2025年 底， ...

Group 1 - The article highlights the convenience and warmth of "Internet + nursing services" for newborn families, allowing them to receive professional care at home during cold weather [5][7] - A nurse visits a family with newborn twins, providing care and guidance on health and nutrition, emphasizing the importance of maternal well-being for breastfeeding and the babies' health [5][6] - Parents express gratitude for the home service, noting the ease of receiving care without having to take their children out in the cold [7][8] Group 2 - The nurse provides practical advice, such as maintaining air circulation by opening windows and being available for questions through the service platform [8] - The parents rate the service highly, reflecting their satisfaction and the positive impact of the home visit on their winter experience [8]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Tongce Medical (600763), including stock price movement and trading volume [1] - As of January 26, 2026, Tongce Medical's stock closed at 46.47 yuan, down 0.71%, with a turnover rate of 1.85% and a trading volume of 82,900 hands, resulting in a transaction amount of 385 million yuan [1] - The net capital outflow from major funds was 5.29 million yuan, accounting for 1.38% of the total transaction amount, while retail investors saw a net inflow of 4.94 million yuan, representing 1.28% of the total transaction amount [1] Group 2 - In the third quarter of 2025, Tongce Medical reported a main revenue of 842 million yuan, an increase of 2.34% year-on-year, and a net profit attributable to shareholders of 192 million yuan, up 2.31% year-on-year [2] - The company's total revenue for the first three quarters of 2025 reached 2.29 billion yuan, reflecting a year-on-year growth of 2.56%, with a net profit of 514 million yuan, which is a 3.16% increase year-on-year [2] - The company's debt ratio stands at 25.1%, with an investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while the gross profit margin is reported at 41.69% [2] Group 3 - Over the past 90 days, five institutions have provided ratings for Tongce Medical, with three buy ratings and two hold ratings, and the average target price set at 52.15 yuan [2]

经济观察网 2026年1月26日，国际医学(000516)发布2025年度业绩预告，预计2025年净利润亏损3.15亿 元至2.95亿元，同比下降16.08%至23.95%；扣除非经常性损益后的净利润亏损3.5亿元至3.2亿元，同比 下降11.53%至21.98%。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown weaker performance compared to the overall market, with a TTM P/E ratio of 38.51x, which is at the 84.35th percentile of the past five years [1][37]. - The report highlights the importance of the CXO sector, emphasizing the competitive advantages of Chinese companies in the chemical CDMO field, and suggests that the sector's valuation is expected to recover [41]. - The report recommends focusing on innovative drugs and the associated industry chain, with a notable mention of the upcoming JPM conference and the clinical progress of innovative drugs overseas [41][42]. Summary by Sections Market Performance - The overall A-share market increased by 1.17%, while the biotechnology sector declined by 0.39%. The medical services sector was the worst performer, dropping by 2.17% [1][32]. - The report notes that the largest sub-sectors by holding percentage are chemical preparations (37.5%) and other biological products (20.8%) [19]. Fund Holdings Analysis - As of Q4 2025, the total net asset value of pharmaceutical funds reached 358.4 billion, a decrease of 9.0% from the previous quarter [11]. - The report indicates that the pharmaceutical holdings of all funds accounted for 7.97%, down by 1.71 percentage points [16]. Key Company Earnings Forecasts - The report provides earnings forecasts for several key companies, all rated "Outperform": - Mindray Medical (300760.SZ): 2024A net profit of 11.67 billion [4] - WuXi AppTec (603259.SH): 2024A net profit of 9.35 billion [4] - Aier Eye Hospital (300015.SZ): 2024A net profit of 3.56 billion [4] - New Industry (300832.SZ): 2024A net profit of 1.83 billion [4] - Huatai Medical (688617.SH): 2024A net profit of 670 million [4] Investment Strategy - The report recommends a portfolio of stocks including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, focusing on companies with strong growth potential in the innovative drug sector [42][43].

Core Viewpoint - International Medical is expected to report a net profit loss of between 295 million yuan and 315 million yuan for the full year of 2025 due to market fluctuations and DRG payment policy reforms impacting revenue [1] Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [1] - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [1] - The net profit excluding non-recurring items was -312 million yuan, a decline of 41.94% year-on-year [1] - In the third quarter of 2025, the company's single-quarter main revenue was 961 million yuan, a year-on-year decrease of 18.95% [1] - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [1] - The single-quarter net profit excluding non-recurring items was -123 million yuan, down 52.03% year-on-year [1] Operational Metrics - The company's debt ratio stands at 68.8% [1] - Investment income reported was 20.7586 million yuan [1] - Financial expenses amounted to 111 million yuan [1] - The gross profit margin is recorded at 6.59% [1]